Subjects -> MEDICAL SCIENCES (Total: 8642 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (218 journals)
    - ANAESTHESIOLOGY (120 journals)
    - CARDIOVASCULAR DISEASES (338 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (21 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (234 journals)
    - DENTISTRY (293 journals)
    - DERMATOLOGY AND VENEREOLOGY (164 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (121 journals)
    - ENDOCRINOLOGY (150 journals)
    - FORENSIC SCIENCES (42 journals)
    - GASTROENTEROLOGY AND HEPATOLOGY (188 journals)
    - GERONTOLOGY AND GERIATRICS (138 journals)
    - HEMATOLOGY (157 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (174 journals)
    - LABORATORY AND EXPERIMENTAL MEDICINE (99 journals)
    - MEDICAL GENETICS (58 journals)
    - MEDICAL SCIENCES (2392 journals)
    - NURSES AND NURSING (364 journals)
    - OBSTETRICS AND GYNECOLOGY (207 journals)
    - ONCOLOGY (384 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (140 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (170 journals)
    - OTORHINOLARYNGOLOGY (83 journals)
    - PATHOLOGY (100 journals)
    - PEDIATRICS (275 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (158 journals)
    - PSYCHIATRY AND NEUROLOGY (833 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (192 journals)
    - RESPIRATORY DISEASES (104 journals)
    - RHEUMATOLOGY (79 journals)
    - SPORTS MEDICINE (81 journals)
    - SURGERY (406 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (155 journals)

MEDICAL SCIENCES (2392 journals)            First | 4 5 6 7 8 9 10 11 | Last

Showing 1401 - 1600 of 3562 Journals sorted alphabetically
Journal of the Grodno State Medical University     Open Access   (Followers: 1)
Journal of the History of Medicine and Allied Sciences     Hybrid Journal   (Followers: 17)
Journal of the International Society for Telemedicine and eHealth     Open Access   (Followers: 3)
Journal of the Learning Sciences     Hybrid Journal   (Followers: 17)
Journal of the Medical Library Association     Open Access   (Followers: 288)
Journal of the Medical Sciences (Berkala ilmu Kedokteran)     Open Access   (Followers: 1)
Journal of the National Medical Association     Full-text available via subscription  
Journal of the Peripheral Nervous System     Hybrid Journal   (Followers: 3)
Journal of the Postgraduate Institute of Medicine     Open Access  
Journal of the Renin-Angiotensin-Aldosterone System     Open Access   (Followers: 1)
Journal of the Royal Society of Medicine     Hybrid Journal   (Followers: 2)
Journal of the Ruhunu Clinical Society     Open Access  
Journal of the Scientific Society     Open Access   (Followers: 1)
Journal of the Siena Academy of Sciences     Open Access   (Followers: 1)
Journal of Therapeutic Ultrasound     Open Access  
Journal of Thyroid Research     Open Access   (Followers: 1)
Journal of Tissue Engineering     Open Access   (Followers: 6)
Journal of Tissue Viability     Full-text available via subscription   (Followers: 3)
Journal of Topology     Hybrid Journal   (Followers: 1)
Journal of Toxicology     Open Access   (Followers: 11)
Journal of Traditional Chinese Medical Sciences     Open Access   (Followers: 1)
Journal of Traditional Chinese Medicine     Open Access   (Followers: 4)
Journal of Transition Medicine     Open Access  
Journal of Translational Medicine     Open Access   (Followers: 4)
Journal of Transplantation & Stem Cell Biology     Open Access   (Followers: 1)
Journal of Ultrasonography     Open Access   (Followers: 1)
Journal of Ultrasound     Hybrid Journal   (Followers: 4)
Journal of Ultrasound in Medicine     Full-text available via subscription   (Followers: 12)
Journal of Universal College of Medical Sciences     Open Access   (Followers: 1)
Journal of University Medical & Dental College     Open Access   (Followers: 1)
Journal of University of Babylon for Pure and Applied Sciences     Open Access  
Journal of Vascular Research     Full-text available via subscription   (Followers: 2)
Journal of Vector Borne Diseases     Open Access   (Followers: 1)
Journal of Visualized Experiments     Full-text available via subscription   (Followers: 5)
Journal of Wound Care     Full-text available via subscription   (Followers: 33)
JPSCR : Journal of Pharmaceutical Science and Clinical Research     Open Access   (Followers: 1)
JRSM Open     Open Access  
Jundishapur Journal of Health Sciences     Open Access  
Jurnal Berkala Epidemiologi     Open Access   (Followers: 1)
Jurnal Berkala Kesehatan     Open Access  
Jurnal Ergonomi Indonesia (The Indonesian Journal of Ergonomic)     Open Access   (Followers: 2)
Jurnal Farmasi Galenika (Galenika Journal of Pharmacy)     Open Access   (Followers: 1)
Jurnal Ilmiah Kesehatan     Open Access  
Jurnal Kedokteran dan Kesehatan Indonesia     Open Access  
Jurnal Kesehatan     Open Access   (Followers: 1)
Jurnal Kesehatan Andalas     Open Access   (Followers: 5)
Jurnal Penyakit Dalam Indonesia     Open Access   (Followers: 1)
Jurnal PROMKES : Jurnal Promosi Kesehatan dan Pendidikan Kesehatan Indonesia (The Indonesian Journal of Health Promotion and Health Education)     Open Access  
Jurnal Sains Kesihatan Malaysia (Malaysian Journal of Health Sciences)     Open Access  
Jurnal Teknologi Laboratorium     Open Access  
Jurnal Vektor Penyakit     Open Access  
Juxta : Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga     Open Access  
Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi     Open Access  
Kaleidoscope     Open Access  
Kansas Journal of Medicine     Open Access   (Followers: 2)
Kaohsiung Journal of Medical Sciences     Open Access  
Karaelmas Science and Engineering Journal     Open Access   (Followers: 1)
Kasmera     Open Access   (Followers: 2)
Kasr Al Ainy Medical Journal     Open Access   (Followers: 1)
Keio Journal of Medicine     Partially Free  
Kerbala Journal of Medicine     Open Access   (Followers: 1)
Kind & Adolescent     Hybrid Journal   (Followers: 4)
Kind & Adolescent Praktijk     Hybrid Journal   (Followers: 2)
Kinésithérapie, la Revue     Full-text available via subscription   (Followers: 1)
Kırıkkale Üniversitesi Tıp Fakültesi Dergisi     Open Access  
Klinische Monatsblätter für Augenheilkunde     Hybrid Journal   (Followers: 1)
Klinische Pädiatrie     Hybrid Journal   (Followers: 1)
KMA - Das Gesundheitswirtschaftsmagazin     Hybrid Journal   (Followers: 2)
KnE Medicine     Open Access   (Followers: 1)
Knie Journal     Hybrid Journal   (Followers: 2)
Kocaeli Ãœniversitesi SaÄŸlık Bilimleri Dergisi     Open Access   (Followers: 3)
Kocatepe Tıp Dergisi     Open Access  
Komplementäre und Integrative Medizin     Full-text available via subscription  
Konuralp Medical Journal / Konuralp Tıp Dergisi     Open Access  
Korean Journal of Family Medicine     Open Access  
Korean Journal of Medical History     Open Access  
Krankenhaushygiene up2date     Hybrid Journal   (Followers: 1)
KYAMC Journal     Open Access  
L'Encéphale     Full-text available via subscription   (Followers: 1)
La Ciencia al Servicio de la Salud y Nutrición     Open Access  
La Lettre de Médecine Physique et de Réadaptation     Hybrid Journal   (Followers: 1)
La Medicina del Lavoro     Partially Free   (Followers: 1)
La Presse Médicale     Full-text available via subscription   (Followers: 3)
La Revue de Médecine Légale     Full-text available via subscription  
La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine     Hybrid Journal  
Laboratory Animals     Hybrid Journal   (Followers: 17)
Laboratory Medicine     Full-text available via subscription   (Followers: 7)
Läkartidningen     Partially Free   (Followers: 21)
Laparoscopic, Endoscopic and Robotic Surgery     Open Access  
Laryngo-Rhino-Otologie     Hybrid Journal   (Followers: 3)
Legal Medicine     Hybrid Journal   (Followers: 356)
Leprosy Review     Full-text available via subscription   (Followers: 1)
Leviathan     Hybrid Journal   (Followers: 2)
Libyan International Medical University Journal     Open Access   (Followers: 2)
Libyan Journal of Medical Sciences     Open Access  
Libyan Journal of Medicine     Open Access  
Life Science Alliance     Open Access   (Followers: 1)
Life Sciences     Hybrid Journal   (Followers: 6)
Life Writing     Hybrid Journal   (Followers: 2)
Lifestyle Journal     Open Access   (Followers: 1)
Linacre Quarterly     Hybrid Journal   (Followers: 1)
Lippincott’s Bone and Joint Newsletter     Full-text available via subscription  
Literature and Medicine     Full-text available via subscription   (Followers: 9)
Living Ethics : Newsletter of the St. James Ethics Centre     Full-text available via subscription  
Logopedics Phoniatrics Vocology     Hybrid Journal   (Followers: 17)
London Journal of Primary Care     Open Access   (Followers: 1)
Lupus     Hybrid Journal   (Followers: 4)
Lupus Science & Medicine     Open Access   (Followers: 2)
Luts     Hybrid Journal   (Followers: 2)
Lymphatic Research and Biology     Hybrid Journal   (Followers: 2)
Maatwerk     Hybrid Journal   (Followers: 1)
mAbs     Full-text available via subscription   (Followers: 18)
Macedonian Medical Electronic Journal     Open Access  
Macedonian Medical Review     Open Access  
Magnetic Resonance Insights     Open Access   (Followers: 2)
Majalah Kedokteran Andalas     Open Access  
Majalah Kedokteran Bandung     Open Access  
Majalah Sainstekes / Sainstekes Magazine     Open Access  
Malaria Research and Treatment     Open Access   (Followers: 4)
Malawi Medical Journal     Open Access   (Followers: 6)
MAMC Journal of Medical Sciences     Open Access  
Managed Care     Free   (Followers: 3)
Manuelle Medizin     Hybrid Journal   (Followers: 1)
manuelletherapie     Hybrid Journal  
Marshall Journal of Medicine     Open Access  
Mathematical Medicine and Biology: A Journal of the IMA     Hybrid Journal   (Followers: 1)
Matrix Science Medica     Open Access  
Mayo Clinic Proceedings     Full-text available via subscription   (Followers: 17)
Mayo Clinic Proceedings : Innovations, Quality & Outcomes     Open Access   (Followers: 1)
McMaster University Medical Journal     Open Access   (Followers: 2)
Med Phoenix     Open Access  
Médecine & Droit     Full-text available via subscription  
Médecine & Longévité     Full-text available via subscription   (Followers: 1)
Médecine & Nutrition     Full-text available via subscription  
Médecine des Maladies Métaboliques     Full-text available via subscription   (Followers: 1)
Médecine du Sommeil     Full-text available via subscription  
Médecine Nucléaire     Full-text available via subscription   (Followers: 1)
Médecine Palliative : Soins de Support - Accompagnement - Éthique     Full-text available via subscription   (Followers: 2)
médecine/sciences     Full-text available via subscription   (Followers: 2)
Medical and Biological Engineering and Computing     Hybrid Journal   (Followers: 4)
Medical and Biological Sciences     Open Access   (Followers: 1)
Medical Cannabis and Cannabinoids     Open Access   (Followers: 2)
Medical Care     Hybrid Journal   (Followers: 12)
Medical Care Research and Review     Hybrid Journal   (Followers: 2)
Medical Case Reports Journal     Open Access  
Medical Case Studies     Open Access   (Followers: 2)
Medical Clinics of North America     Full-text available via subscription   (Followers: 4)
Medical Devices & Sensors     Hybrid Journal   (Followers: 1)
Medical Devices: Evidence and Research     Open Access   (Followers: 3)
Medical Dosimetry     Hybrid Journal   (Followers: 5)
Medical Education Development     Open Access   (Followers: 15)
Medical Education Online     Open Access   (Followers: 34)
Medical Education Scholarship Forum Proceedings     Open Access   (Followers: 2)
Medical Engineering & Physics     Hybrid Journal   (Followers: 8)
Medical Equipment Insights     Open Access  
Medical Ethics     Open Access   (Followers: 4)
Medical History     Hybrid Journal   (Followers: 8)
Medical Humanities     Hybrid Journal   (Followers: 21)
Medical Hypotheses     Hybrid Journal   (Followers: 5)
Medical Informatics and Engineering     Open Access   (Followers: 2)
Medical Innovation & Business     Full-text available via subscription   (Followers: 2)
Medical Instrumentation     Open Access  
Medical Journal Armed Forces India     Full-text available via subscription  
Medical Journal of Babylon     Open Access  
Medical Journal of Basrah University     Open Access   (Followers: 1)
Medical Journal of Chinese People's Liberation Army     Open Access  
Medical Journal of Dr. D.Y. Patil University     Open Access  
Medical Journal of Dr. D.Y. Patil Vidyapeeth     Open Access  
Medical Journal of Indonesia     Open Access   (Followers: 2)
Medical Journal of Pokhara Academy of Health Sciences     Open Access  
Medical Journal of Shree Birendra Hospital     Open Access   (Followers: 1)
Medical Journal of the Islamic Republic of Iran     Open Access   (Followers: 2)
Medical Journal of Zambia     Open Access  
Medical Law Cases for Doctors     Open Access   (Followers: 5)
Medical Law International     Hybrid Journal   (Followers: 8)
Medical Molecular Morphology     Hybrid Journal  
Medical Mycology Case Reports     Open Access  
Medical Perspectives     Full-text available via subscription   (Followers: 1)
Medical Photonics     Hybrid Journal   (Followers: 1)
Medical Physics     Hybrid Journal   (Followers: 18)
Medical Practice and Reviews     Open Access   (Followers: 3)
Medical Principles and Practice     Open Access  
Medical Research Journal     Partially Free   (Followers: 1)
Medical Research Journal     Open Access  
Medical Science and Discovery     Open Access  
Medical Science Educator     Hybrid Journal   (Followers: 3)
Medical Sciences     Open Access  
Medical Sciences     Open Access   (Followers: 2)
Medical Technology SA     Full-text available via subscription  
Medical University     Open Access  
Medical Writing     Hybrid Journal   (Followers: 4)
MEDICC Review     Open Access  
Medicentro Electrónica     Open Access  
Medicina     Open Access   (Followers: 1)
Medicina & Storia     Full-text available via subscription   (Followers: 1)
Medicina (Buenos Aires)     Open Access   (Followers: 4)
Medicina Clínica     Full-text available via subscription   (Followers: 7)
Medicina Clínica (English Edition)     Hybrid Journal   (Followers: 1)
Medicina Clínica Práctica     Open Access  
Medicina General y de Familia     Open Access  

  First | 4 5 6 7 8 9 10 11 | Last

Similar Journals
Journal Cover
Lupus Science & Medicine
Journal Prestige (SJR): 1.625
Citation Impact (citeScore): 3
Number of Followers: 2  

  This is an Open Access Journal Open Access journal
ISSN (Online) 2053-8790
Published by BMJ Publishing Group Homepage  [68 journals]
  • Characterisation of anifrolumab, a fully human anti-interferon receptor
           antagonist antibody for the treatment of systemic lupus erythematosus

    • Authors: Riggs, J. M; Hanna, R. N, Rajan, B, Zerrouki, K, Karnell, J. L, Sagar, D, Vainshtein, I, Farmer, E, Rosenthal, K, Morehouse, C, de los Reyes, M, Schifferli, K, Liang, M, Sanjuan, M. A, Sims, G. P, Kolbeck, R.
      Abstract: ObjectiveWe investigated the mechanistic and pharmacological properties of anifrolumab, a fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal antibody in development for SLE.MethodsIFNAR1 surface expression and internalisation on human monocytes before and after exposure to anifrolumab were assessed using confocal microscopy and flow cytometry. The effects of anifrolumab on type I IFN pathway activation were assessed using signal transducer and activator of transcription 1 (STAT1) phosphorylation, IFN-stimulated response element–luciferase reporter cell assays and type I IFN gene signature induction. The ability of anifrolumab to inhibit plasmacytoid dendritic cell (pDC) function and plasma cell differentiation was assessed by flow cytometry and ELISA. Effector-null properties of anifrolumab were assessed in antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) assays with B cells.ResultsAnifrolumab reduced cell surface IFNAR1 by eliciting IFNAR1 internalisation. Anifrolumab blocked type I IFN-dependent STAT1 phosphorylation and IFN-dependent signalling induced by recombinant and pDC-derived type I IFNs and serum of patients with SLE . Anifrolumab suppressed type I IFN production by blocking the type I IFN autoamplification loop and inhibited proinflammatory cytokine induction and the upregulation of costimulatory molecules on stimulated pDCs. Blockade of IFNAR1 suppressed plasma cell differentiation in pDC/B cell co-cultures. Anifrolumab did not exhibit CDC or ADCC activity.ConclusionsAnifrolumab potently inhibits type I IFN-dependent signalling, including the type I IFN autoamplification loop, and is a promising therapeutic for patients with SLE and other diseases that exhibit chronic dysfunctional type I IFN signalling.
      Keywords: Open access
      PubDate: 2018-04-05T06:57:31-07:00
      DOI: 10.1136/lupus-2018-000261
      Issue No: Vol. 5, No. 1 (2018)
       
  • Thank you to our reviewers 2017

    • Keywords: Open access
      PubDate: 2018-03-28T23:11:07-07:00
      DOI: 10.1136/lupus-2017-reviewers
      Issue No: Vol. 5, No. 1 (2018)
       
  • Safety, tolerability and pharmacokinetics of subcutaneous and intravenous
           anifrolumab in healthy volunteers

    • Authors: Tummala, R; Rouse, T, Berglind, A, Santiago, L.
      Abstract: ObjectivesTo compare the pharmacokinetics (PK), safety and tolerability of subcutaneous (SC) and intravenous anifrolumab, an anti–type I interferon receptor monoclonal antibody in development for SLE, in healthy volunteers.MethodsIn this Phase I randomised, placebo-controlled study, 30 adults were assigned to three treatment cohorts (anifrolumab 300 mg SC (n=6), anifrolumab 300 mg intravenous (n=6), anifrolumab 600 mg SC (n=6)) and placebo (n=4/cohort). Serial blood samples were collected up to Day 84 to measure anifrolumab concentrations and antidrug antibodies (ADAs). PK parameters were estimated by noncompartmental analysis.ResultsMaximum serum concentrations in SC cohorts occurred after 4–7 days. Anifrolumab serum concentrations were below the limit of detection in all individuals by Day 84. Exposure to SC anifrolumab increased dose proportionally from 300 mg to 600 mg based on area under the serum concentration-time curve. Anifrolumab 300 mg SC exposure reached 87% of the intravenous exposure. Anifrolumab 300 mg SC and placebo administration elicited minimal injection-site reactions. Transient injection-site induration occurred in five of six individuals after anifrolumab 600 mg SC and two of four individuals after placebo. Transient, mild to moderate injection-site induration and pruritus occurred simultaneously in two of six individuals after anifrolumab 600 mg SC. Adverse events were reported by 50% (n=9) of anifrolumab-treated individuals and 33% (n=4) of placebo-treated individuals. ADAs were detected in only one individual in the anifrolumab 300-mg intravenous group at the Day 84 assessment.ConclusionAnifrolumab 300-mg SC exposure was 87% of intravenous administration, with single SC anifrolumab administrations well tolerated in healthy volunteers.
      Keywords: Open access
      PubDate: 2018-03-23T22:16:11-07:00
      DOI: 10.1136/lupus-2017-000252
      Issue No: Vol. 5, No. 1 (2018)
       
  • Lupus community panel proposals for optimising clinical trials: 2018

    • Authors: Merrill, J. T; Manzi, S, Aranow, C, Askenase, A, Bruce, I, Chakravarty, E, Chong, B, Costenbader, K, DallEra, M, Ginzler, E, Hanrahan, L, Kalunian, K, Merola, J, Raymond, S, Rovin, B, Saxena, A, Werth, V. P.
      Abstract: Formidable impediments stand in the way of treatment development for lupus. These include the unwieldy size of current trials, international competition for scarce patients, complex outcome measures and a poor understanding of these outcomes in the world at large. The heterogeneity of the disease itself coupled to superimposition of variegated background polypharmacy has created enough immunological noise to virtually ensure the failure of lupus treatment trials, leaving an understandable suspicion that at least some of the results in testing failed drugs over the years may not have been negative, but merely uninterpretable. The authors have consulted with many clinical trial investigators, biopharmaceutical developers and stakeholders from government and voluntary sectors. This paper examines the available evidence that supports workable trial designs and proposes approaches to improve the odds of completing interpretable treatment development programs for lupus.
      Keywords: Clinical trials (epidemiology), Open access
      PubDate: 2018-03-23T02:00:19-07:00
      DOI: 10.1136/lupus-2018-000258
      Issue No: Vol. 5, No. 1 (2018)
       
  • Risk of adverse events from different drugs for SLE: a systematic review
           and network meta-analysis

    • Authors: Tian, J; Luo, Y, Wu, H, Long, H, Zhao, M, Lu, Q.
      Abstract: ObjectiveThe comparative safety of immunosuppressive drugs, biologicals and glucocorticoids (GC) for patients with SLE remains controversial. We aimed to investigate the specific side effects of the available SLE drugs in this population of patients.MethodsElectronic databases were systematically searched through September 2017 for randomised trials in patients with SLE. The primary outcomes were all-cause mortality and withdrawal related to adverse events (AEs). We performed a random-effects network meta-analysis to obtain estimates for primary and secondary outcomes and presented these estimates as ORs with 95% CIs.ResultsForty-four studies comprising 9898 participants were included in the network meta-analysis. No drug regimen was considered to be safer for reducing all-cause mortality. However, compared with cyclophosphamide, azathioprine (OR 3.04, 95% CI (1.44 to 6.42)) and cyclosporine (OR 3.28, 95% CI (1.04 to 10.35)) were significantly less safety in AE-related withdrawals, and GC was ranked lowest and led to higher withdrawal rates. Tacrolimus (TAC) was ranked high and showed a benefit in many outcomes. Biologicals and chloroquine also showed good safety in all of the available outcomes, while the beneficial effects of other immunosuppressive drugs were not substantial in different types of serious adverse events.ConclusionsTAC is the safest strategy for patients with SLE. Biologicals and chloroquine are also fairly safe for patients with SLE. The use of other immunosuppressive drugs and GC needs to be balanced against the potential harms of different types of AEs, and the practical safety of drug combinations still requires further trials to evaluate.
      Keywords: Open access
      PubDate: 2018-03-09T06:40:05-08:00
      DOI: 10.1136/lupus-2017-000253
      Issue No: Vol. 5, No. 1 (2018)
       
  • Remission and low disease activity in systemic lupus erythematosus: an
           achievable goal even with fewer steroids' Real-life data from a
           monocentric cohort

    • Authors: Tani, C; Vagelli, R, Stagnaro, C, Carli, L, Mosca, M.
      Abstract: ObjectivesTo evaluate what proportion of patients fulfil the DORIS definition of remission, the definition of lupus low disease activity state (LLDAS) and LLDAS with a glucocorticoid (GC) dosage ≤5 (LLDAS5) in a longitudinal monocentric cohort of patients with SLE; to identify predictors of sustained remission and LLDAS attainment; to evaluate the effect of sustained remission and LLDAS on damage accrual over a period of 5 years and compare the two conditions in terms of clinical outcomes.MethodsRetrospective analysis of data prospectively collected from patients with SLE followed from 2012 to 2016.Results115 patients were included in this analysis. At baseline, 72% of patients were on LLDAS and almost all patients also fulfilled the LLDAS5 definition; 45% of patients were in remission on treatment, 12% were in remission off treatment, 26% were in complete remission on treatment, 2% were in complete remission off treatment. Disease activity at baseline was the strongest predictor of subsequent LLDAS and remission; the presence of joint and cutaneous manifestations was associated with a minor likelihood to achieve LLDAS or remission during follow-up.Patients in remission and LLDAS for the whole follow-up period accrued significantly less organ damage; on the contrary, patients who maintained all kinds of remissions or LLDAS for less than 50% of the time did not show any differences in damage accrual with respect to the rest of the cohort.ConclusionRemission and LLDAS, even with reduced GC use, are an achievable goal in clinical practice; sustained LLDAS and remission are both associated with reduced damage accrual.
      Keywords: Open access
      PubDate: 2018-02-27T21:33:25-08:00
      DOI: 10.1136/lupus-2017-000234
      Issue No: Vol. 5, No. 1 (2018)
       
  • Unique clinical characteristics, autoantibodies and medication use in
           Native American patients with systemic lupus erythematosus

    • Authors: Kheir, J. M; Guthridge, C. J, Johnston, J. R, Adams, L. J, Rasmussen, A, Gross, T. F, Munroe, M. E, Bourn, R. L, Sivils, K. L, Guthridge, J. M, Weisman, M. H, Wallace, D. J, Anaya, J.-M, Rojas Villarraga, A, Jarvis, J. N, Harley, J. B, James, J. A.
      Abstract: ObjectiveSystemic lupus erythematosus (SLE) is a systemic autoimmune disease with varied morbidity and mortality. We assessed clinical presentations, autoantibody specificities and therapeutic interventions in Native American (NA) patients with SLE.MethodsPatients with SLE meeting 1997 American College of Rheumatology classification criteria (n=3148) were enrolled between 1992 and 2010 in the multiethnic, cross-sectional Lupus Family Registry and Repository. Clinical, demographic and therapeutic information were extracted from medical records using a standardised form and formalised training. Autoantibodies were assessed by indirect immunofluorescence (antinuclear antibodies (ANA) and antidouble-stranded DNA), precipitin (ENA) and ELISA (IgG and IgM anticardiolipins).ResultsNA patients met SLE classification at a younger age (29.89±12.3 years) than European Americans (EA; 32.02±12.87, P=0.0157) and a similar age to African-Americans (AAs) and Hispanics (HIS). More NA patients had concurrent rheumatic diseases or symptoms, such as Raynaud’s phenomenon, interstitial lung disease, Sjögren’s syndrome and systemic sclerosis. Compared with EAs, NAs were more likely to have high-titre ANA (≥1:3240; P
      Keywords: Open access
      PubDate: 2018-02-27T21:33:25-08:00
      DOI: 10.1136/lupus-2017-000247
      Issue No: Vol. 5, No. 1 (2018)
       
  • Mouse models of lupus: what they tell us and what they dont

    • Authors: Richard, M. L; Gilkeson, G.
      Abstract: Lupus is a complex heterogeneous disease characterised by autoantibody production and immune complex deposition followed by damage to target tissues. Animal models of human diseases are an invaluable tool for defining pathogenic mechanisms and testing of novel therapeutic agents. There are perhaps more applicable murine models of lupus than any other human disease. There are spontaneous models of lupus, inducible models of lupus, transgenic-induced lupus, gene knockout induced lupus and humanised mouse models of lupus. These mouse models of lupus have contributed significantly to our knowledge of the pathogenesis of lupus and served as valuable preclinical models for proof of concept for new therapies. Despite their utility, mouse models of lupus have their distinct limitations. Although similar, mouse and human immune systems are different and thus one cannot assume a mechanism for disease in one is translatable to the other. Efficacy and toxicity of compounds can vary significantly between humans and mice, also limiting direct translation. Finally, the heterogeneous aspects of human lupus, both in clinical presentation, underlying pathogenesis and genetics, are not completely represented in current mouse models. Thus, proving a therapy or mechanism of disease in one mouse model is similar to proving a mechanism/therapy in a limited subset of human lupus. These limitations, however, do not marginalise the importance of animal models nor the significant contributions they have made to our understanding of lupus.
      Keywords: Open access
      PubDate: 2018-01-21T23:30:18-08:00
      DOI: 10.1136/lupus-2016-000199
      Issue No: Vol. 5, No. 1 (2018)
       
  • Associations between type I interferon and antiphospholipid antibody
           status differ between ancestral backgrounds

    • Authors: Iwamoto, T; Dorschner, J, Jolly, M, Huang, X, Niewold, T. B.
      Abstract: ObjectiveThe type I interferon pathway is activated in many patients with systemic lupus erythematosus (SLE), and anti-double-stranded DNA (dsDNA) and anti-RNA binding protein autoantibodies are correlated with high interferon-α (IFNα) activity. We studied whether antiphospholipid (APL) antibodies, which should not stimulate Toll-like receptors, are also associated with high levels of IFNα activity.MethodsSerum IFNα activity was measured in patients with SLE using the WISH cell bioassay. IgG APL, anti-RBP and anti-dsDNA antibodies were measured in the clinical laboratory, and standard clinical cut-offs were used to define the positive results.ResultsHigh IFNα activity was associated with anti-RBP and anti-dsDNA antibodies in all three ancestral backgrounds. Strikingly, African-American subjects with a positive APL antibody test had higher IFNα activity than those without IgG APL antibodies. This was not shared with other ancestral backgrounds. This finding was independent of other autoantibody profiles, and clinical features did not differ between IgG APL antibody positive versus negative African-American patients.ConclusionThe difference in association between IFNα activity and IgG APL status between ancestral backgrounds supports differences in molecular pathogenesis. This may suggest B cell hyperactivity in the setting of type I IFN in African-Americans and could suggest ways to individualise therapy.
      Keywords: Open access
      PubDate: 2018-01-13T03:51:55-08:00
      DOI: 10.1136/lupus-2017-000246
      Issue No: Vol. 5, No. 1 (2018)
       
  • Very delayed lupus nephritis: a report of three cases and literature
           review

    • Authors: Alexandre, A. R; Carreira, P. L, Isenberg, D. A.
      Abstract: Lupus nephritis (LN) affects up to 50% of patients with Systemic Lupus Erythematosus (SLE) and is associated with a worse prognosis. LN usually develops within the first 5 years of the onset of the disease. We report three patients with very delayed LN (DLN) diagnosed after 15 or more years after SLE diagnosis. The three patients were non-Caucasian women with adolescent or adult-onset SLE. Each had antinuclear, anti-dsDNA and anti-Ro antibodies. Hydroxychloroquine was prescribed for each. Their disease courses were characterised by sporadic non-renal flares controlled by steroids and, in two cases, by one cycle of rituximab. Unexpectedly, they developed proteinuria, haematuria and lowering of estimated glomerular filtration rate with clinical signs of renal disease. LN was confirmed by renal biopsy. Reviewing them, each showed serological signs of increasing disease activity (rising levels of anti-dsDNA antibodies and fall in C3) that predated clinical or laboratory signs of LN by 1–3 years. Reviewing the literature, we found a lack of knowledge about DLN starting more than 15 years after SLE diagnosis. With the increasing life expectancy of patients with SLE it is likely that more cases of very DLN will emerge.
      Keywords: Open access
      PubDate: 2018-01-12T20:46:37-08:00
      DOI: 10.1136/lupus-2017-000241
      Issue No: Vol. 5, No. 1 (2018)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 34.231.21.83
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-